European Commission Approves Trodelvy® as a First Line Treatment for Metastatic Triple Negative Breast Cancer Patients Not Candidates for PD (l)1 Inhibitors
The European Commission has approved Gilead Sciences' Trodelvy as a first-line treatment for metastatic triple-negative breast cancer in patients ineligible for PD-(L)1 inhibitors. This marks the first antibody-drug conjugate approved for this specific patient population in the EU.
Why it matters
This approval provides a critical new therapeutic option for patients with one of the most aggressive forms of breast cancer, potentially improving survival outcomes.
News Releases European-Commission-Approves-Trodelvy-as-a-First-Line-Treatment-for-Metastatic-Triple-Negative-Breast-Cancer-Patients-Not-Candidates-for-PD-l1-Inhibitors June 23, 2026 European Commission Approves Trodelvy as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors Back –Trodelvy is the First Antibody-Drug Conjugate (ADC) and First New Treatment Option in 20 Years in Europe for Certain Patients with First-Line Metastatic Triple-Negative Breast Cancer –
The content is a standard corporate press release reporting on regulatory approval, maintaining a factual and neutral tone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in